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Abstract
Attention-deficit/hyperactivity disorder (ADHD) is comorbid with cocaine abuse. Whereas 
initiating ADHD medication in childhood does not alter later cocaine abuse risk, initiating 
medication during adolescence may increase risk. Preclinical work in the Spontaneously 
Hypertensive Rat (SHR) model of ADHD found that adolescent methylphenidate increased 
cocaine self-administration in adulthood, suggesting a need to identify alternatively efficacious 
medications for teens with ADHD. We examined effects of adolescent d-amphetamine treatment 
on strategy set shifting performance during adolescence and on cocaine self-administration and 
reinstatement of cocaine-seeking behavior (cue reactivity) during adulthood in male SHR, Wistar-
Kyoto (inbred control), and Wistar (outbred control) rats. During the set shift phase, adolescent 
SHR needed more trials and had a longer latency to reach criterion, made more regressive errors 
and trial omissions, and exhibited slower and more variable lever press reaction times. d-
Amphetamine improved performance only in SHR by increasing choice accuracy and decreasing 
errors and latency to criterion. In adulthood, SHR self-administered more cocaine, made more 
cocaine-seeking responses, and took longer to extinguish lever responding than control strains. 
Adolescent d-amphetamine did not alter cocaine self-administration in adult rats of any strain, but 
reduced cocaine seeking during the first of seven reinstatement test sessions in adult SHR. These 
findings highlight utility of SHR in modeling cognitive dysfunction and comorbid cocaine abuse 
in ADHD. Unlike methylphenidate, d-amphetamine improved several aspects of flexible learning 
in adolescent SHR and did not increase cocaine intake or cue reactivity in adult SHR. Thus, 
adolescent d-amphetamine was superior to methylphenidate in this ADHD model.
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1. Introduction
Attention-deficit/hyperactivity disorder (ADHD) is a widely prevalent neurodevelopmental 
disorder, affecting up to 11% of children and adolescents [1]. From 2003 to 2011, ADHD 
diagnoses rose 42%, with the largest increase observed in adolescents aged 14–17 [1,2]. 
Today, nearly one in five high school-age boys have an ADHD diagnosis [2]. Individuals 
with ADHD are at high risk for developing substance dependence. Comorbidity estimates of 
ADHD and substance use disorder (SUD) range from 9.5% up to 58%, depending on the 
sample [3,4]. While nicotine, alcohol, and cannabis are most frequently abused by 
individuals with ADHD [5], ADHD patients are more likely than those without ADHD to 
escalate use to other illicit drugs, including cocaine [6]. The lifetime prevalence of cocaine 
use disorder in individuals with ADHD is 23%, compared to 10.8% in those without ADHD 
[7]. Children with ADHD are twice as likely to abuse cocaine or become cocaine dependent 
in adulthood compared to children without an ADHD diagnosis [8].
Over two-thirds of individuals with ADHD are prescribed medication for their symptoms 
[1], the most common of which is the stimulant methylphenidate (Ritalin®) [9,10]. 
Methylphenidate acts by blocking dopamine and norepinephrine transporters (DAT and 
NET), prolonging catecholamine stimulation of post-synaptic receptors [11,12]. Questions 
have been raised regarding the relationship between methylphenidate treatment and 
development of SUD. Initiation of treatment in childhood neither increases nor decreases the 
risk of SUD [13–15]. Some evidence that ADHD medication initiation (methylphenidate in 
particular) during adolescence may have different long-term consequences for adult SUD 
than initiation in childhood is derived from research specifically analyzing age of treatment 
onset. The older the child is when ADHD medication is initiated, the greater the risk of 
developing SUD in adulthood [4,16–18]. Currently, there are no well-controlled studies on 
medication initiation after age 13 in individuals with ADHD. Evaluation of long-term effects 
of adolescent ADHD medication on SUD risk in human populations has been complicated 
by difficulty in controlling certain variables across patients, such as the presence of conduct 
disorder, the precise age at which treatment was initiated, and the prescription of one or 
more other medications, which may convey varying degrees of risk [4].
Preclinical models of ADHD, such as the SHR, can begin to address clinically important 
questions concerning ADHD in teens. SHR exhibit the core symptoms of ADHD, such as 
impulsivity, hyperactivity, inattention, increased novelty seeking, poor working memory and 
behavioral inflexibility [19–25]. Importantly, these deficits are unrelated to hypertension in 
SHR [24,26–28], and can be improved by ADHD medications [22,29–31]. The WKY, 
which is the progenitor strain of the SHR, does not exhibit hyperactivity, impulsivity, or 
hypertension, and is frequently used as an inbred control strain [26]. The WIS, a common 
ancestor to both SHR and WKY, is used as an outbred control strain [32]. Concurrent 
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evaluation of these three strains is necessary to control for genetic homogeneity of the SHR, 
while representing the genetic heterogeneity of the general population.
Compared to WKY and WIS, SHR exhibit several aspects of elevated cocaine abuse risk, 
including faster acquisition of cocaine self-administration, heightened cocaine cue reactivity, 
and greater sensitivity and motivation to pursue cocaine reinforcement across a range of 
cocaine doses [30,33–35]. Initiation of methylphenidate treatment during adolescence 
increased nearly all of these aspects of cocaine abuse risk in SHR, but did not increase risk 
in WKY or WIS control strains [30,33,34]. These findings highlight the need to identify 
alternative medications for teens with ADHD that do not convey increased cocaine abuse 
risk, an issue that preclinical models are well suited to investigate [36,37]. Thus far, we have 
found that adolescent treatment with the non-stimulant atomoxetine (Strattera®), a selective 
NET inhibitor, does not increase cocaine abuse risk in SHR [34,35]. However, as a non-
stimulant, atomoxetine alleviates different symptoms of ADHD than methylphenidate, and 
may not be as clinically efficacious in some individuals [38–40]. Therefore, it is important 
to determine whether other efficacious stimulant medications increase cocaine abuse risk in 
newly diagnosed teenagers with ADHD, who may be initiating treatment.
An alternative stimulant is d-amphetamine (Dexedrine®), which is more efficacious than 
both methylphenidate and atomoxetine in relieving most ADHD symptoms, and has a side-
effect profile similar to that of methylphenidate [41,42]. d-Amphetamine was selected for 
the focus of the current investigation rather than l-amphetamine or the racemic mixture, as 
the d-isomer is more potent than the l-isomer in modulating dopamine transmission [43,44], 
and alleviates more ADHD-related symptoms [45]. Whereas both methylphenidate and d-
amphetamine inhibit DAT and NET function, d-amphetamine also reverses transport [46], 
leading to greater increases in extracellular dopamine than methylphenidate at 
therapeutically relevant doses [47]. Because of this additional mechanism of action, we 
hypothesize that d-amphetamine may have long-term consequences on cocaine abuse risk 
that are different from methylphenidate.
In order to establish SHR as a viable model for adolescent d-amphetamine treatment, it is 
first necessary to determine whether d-amphetamine improves ADHD-related deficits in 
SHR, as it does clinically. In adult SHR, d-amphetamine reduces hyperactivity and 
impulsivity, and improves sustained attention and short- and long-term memory [48,49]. 
However, effects of d-amphetamine in adolescent SHR are not well known. The adolescent 
brain undergoes unique neurochemical changes, including altered expression of dopamine 
D1 and other monoamine receptors [50], suggesting that psychostimulants may differentially 
affect adolescents, relative to juveniles or adults [51]. The current study determined effects 
of d-amphetamine treatment in adolescent WKY, WIS and SHR on performance in a 
strategy set shifting task, analogous to the Wisconsin Card Sorting Task in humans [22,52]. 
If d-amphetamine improves ADHD-related cognitive deficits in adolescent SHR, it then 
becomes important to determine whether adolescent d-amphetamine treatment alters cocaine 
abuse risk in adulthood.
One facet of cocaine abuse risk is reactivity to cocaine cues. Environmental cues associated 
with cocaine use play primary roles in the development of compulsive drug seeking, 
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craving, and relapse [53]. In cocaine users, drug-associated environmental cues trigger 
neural activity and dopamine release in the medial and dorsolateral prefrontal cortex (mPFC/
DLPFC), orbitofrontal cortex (OFC) and striatum, which are regions also dysfunctional in 
ADHD [54–56.] Importantly, dysfunction in these regions is normalized by ADHD 
medication [54–56]. Therefore, the effect of adolescent d-amphetamine on cocaine cue 
reactivity was assessed in adult WKY, WIS, and SHR after treatment was discontinued, as is 
common in young adults with ADHD [57,58]. A second-order schedule of cocaine delivery 
and cue presentation was used to measure cocaine-seeking behavior when cocaine was 
(maintenance phase) and was not (reinstatement phase) available for self-administration 
[59]. Cocaine seeking reflects cue reactivity, a phenomenon associated with cocaine 
addiction that can result in heightened drug use [55,60].
2. Materials and methods
2.1 Subjects
Male WKY/Cr, WIS/Cr, and SHR/Cr rats (Charles River Laboratories, USA) arrived on 
postnatal day 25 (P25). Rats were individually housed in plastic cages with Aspen bedding 
in a temperature- (21–23°C) and light- (07:30 hours on; 19:30 hours off) controlled 
vivarium]. From P28-P55, constituting the rat adolescent period [61], food was restricted to 
achieve ~90% of a growth-adjusted free-feeding body weight to facilitate lever responding 
for food reinforcement during the strategy set-shifting task, and to mimic conditions of past 
comparator studies [22,30,33–35,62]. Animals had free access to water throughout 
experiments and to food after P55. All procedures were approved by the Institutional 
Animal Care and Use Committee at Boston University, and were performed in accordance 
with the National Institutes of Health Guide for the Care and Use of Laboratory Animals 
(Eighth Edition).
2.2 Drugs and treatments
d-Amphetamine sulfate (Sigma-Aldrich, St. Louis, MO, USA) was dissolved in 0.9% sterile 
saline and injected intraperitoneally (i.p.) in a volume of 2 ml/kg to attain a therapeutically 
relevant dose of 0.5 mg/kg. The peak plasma concentration after i.p. administration of 0.5 
mg/kg d-amphetamine is 60 ng/mL [63], which is consistent with the concentrations 
reported in patients with ADHD (64–84 ng/mL) after receiving 0.35–0.58 mg/kg/day oral d-
amphetamine [64]. A dose of 0.5 mg/kg d-amphetamine is considered therapeutically 
relevant also because it is below the threshold for locomotor activation [65] and increases 
dopamine and norepinephrine signaling in PFC [66]. Injections of 0.9% sterile saline (2 
ml/kg) were used for vehicle control. Treatments were administered once daily (Monday–
Friday) during the rat adolescent period (P28-P55) to mimic the weekend medication 
holiday that is often elected by individuals with ADHD [67]. As the half-life of i.p. d-
amphetamine is approximately 1 h in rats compared to 6–7 h in children with ADHD [68–
70], treatments were administered 30 min prior to behavioral testing in the strategy set 
shifting task. This allowed peak monoamine responses to occur and ensured that plasma 
levels reached clinical significance during behavioral testing.
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For intravenous (i.v.) self-administration, cocaine hydrochloride (NIDA, Bethesda, MD, 
USA) was dissolved in 0.9% sterile saline containing 3 IU/ml heparin. A 0.8 mg/ml solution 
of cocaine was infused at a rate of 1.8 ml/min. The infusion duration was adjusted for body 
weight (1.2 s/100 g) to attain a dose of 0.3 mg/kg for self-administration. This dose of 
cocaine produces maximal rates of responding under the second-order schedule of cocaine 
delivery used in the current study [71], and is also consistent with the dose employed in 
prior studies on cocaine self-administration in SHR [30,33–35].
2.3 Apparatus
Experimental chambers (Med Associates, St. Albans, VT, USA) were equipped with two 
response levers, a white stimulus light mounted above each lever, and a house light on the 
opposite wall. All chambers were fitted with a single channel fluid swivel and spring leash 
assembly, connected to a counterbalanced arm (Med Associates). Chambers were enclosed 
in a sound-attenuating cubicle that was equipped with a fan for ventilation and an 8-ohm 
speaker. Pellet dispensers for food delivery and motor-driven syringe pumps for cocaine 
delivery (Med Associates) were located within the cubicle. Experimental events were 
controlled from a PC-compatible computer programmed in Medstate Notation and 
connected to an interface (Med Associates).
2.4. Experiment 1: Strategy set shifting in adolescence
2.4.1 Habituation—An operant version of the strategy set shifting task was used [22,52]. 
On P28, WKY treated with vehicle (n=9) or d-amphetamine (n=9), WIS treated with vehicle 
(n=9) or d-amphetamine (n=9), and SHR treated with vehicle (n=10) or d-amphetamine 
(n=12), received 20 chocolate-flavored pellets in their home cages, to habituate rats to the 
novel food. On P31, all rats began training in experimental chambers. Rats were required to 
lever press under a fixed ratio 1 (FR1) schedule to earn a minimum of 25 chocolate pellet 
reinforcers within a 30-min period. Thereafter, rats began lever retraction training, requiring 
a response within 10-sec of lever insertion into the chamber to earn a chocolate pellet 
reinforcer. Once rats made fewer than 5 omissions for four consecutive 45-min daily 
sessions, lever position bias was established by allowing rats to freely press either lever for 
~10-min. The lever on which the most responses were made was defined as preferred.
2.4.2. Initial set formation—On P42, rats were required to adopt a visual-based strategy 
to earn reinforcement. All set shift test sessions were 2-hr and conducted once daily, 
Monday–Friday. During the initial set formation, each trial began with a 20-sec timeout in a 
dark chamber. After 20 sec, one of the two stimulus lights was illuminated (randomly 
selected for each trial). The house light illuminated 3-sec later, and both response levers 
were inserted into the chamber. Rats were required to press the lever under the illuminated 
stimulus light, regardless of lever bias, to earn a chocolate pellet reinforcer. Levers were 
retracted after a response was made (whether correct or incorrect), or if 10-sec elapsed with 
no response (omission). After a correct response, the stimulus light remained illuminated for 
an additional 4 sec, and a chocolate pellet was delivered 15 sec later. The house light 
remained illuminated until 4 sec after pellet delivery. A 15-sec delay to reinforcement was 
imposed to increase cognitive demand and to better detect strain and treatment differences, 
as SHR are more sensitive to delayed reinforcers than WKY [22,72]. After an incorrect 
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response or a trial omission, the stimulus and house lights were immediately extinguished 
and a new trial was initiated. Training on the initial set formation continued until criterion 
was reached, defined as making 8 consecutive correct responses, following Floresco et al 
[52] and Harvey et al [22].
2.4.3. Set shift—On the day following completion of the initial set formation, rats were 
required to shift responding to a spatial-based discrimination strategy. During this phase, 
animals were required to press the lever opposite the lever position bias to earn 
reinforcement, regardless of which stimulus light was illuminated. Trial contingencies were 
otherwise identical to the initial set formation phase. Training on the set shift phase 
continued until rats made 10 consecutive correct responses [22,52].
2.4.4. Reversal learning—On the day following completion of the set shift phase, 
reversal learning was assessed. During this final phase of the task, rats were required to 
press the lever on the same side as the lever position bias, regardless of which stimulus light 
was illuminated. Trial contingencies were otherwise identical to those of the initial set and 
set shift phases. Training on reversal learning continued until rats made 10 consecutive 
correct responses [22,52].
2.5. Experiment 2: Cocaine self-administration in adulthood
2.5.1. Surgery—d-Amphetamine treatment was discontinued after P55. On P67, rats were 
implanted with intravenous catheters connected to headmounts to enable cocaine self-
administration. Catheters were made from silicon tubing (i.d. = 0.51, o.d. = 0.94 mm) and 
implanted into the right femoral vein. The unsecured end of the catheter was connected to a 
22-gauge L-shaped pedestal mount (Plastics One, Roanoke, VA, USA), secured to the skull 
with four stainless-steel anchor screws and acrylic cement. When not in use, the pedestal 
was sealed with an obdurator and protected with a dust cap. Surgical anesthesia was 
achieved using i.p. ketamine (90 mg/kg; Fort Dodge Animal Health, Fort Dodge, IA, USA) 
and xylazine (8 mg/kg; Akorn, Decatur, IL, USA). Buprenex (0.05 mg/kg, subcutaneous 
[s.c.]; Reckitt Benckiser Healthcare, UK) was used as a preemptive analgesic immediately 
preceding surgery and for up to 48 hrs post-surgery. The antibiotic Baytril (5 mg/kg, i.v.; 
Bayer HealthCare, Shawnee, Mission, KS, USA) was given for up to 5 days post-surgery, 
and the anti-inflammatory Meloxicam (0.3 mg/kg, s.c., Boehringer Ingelheim Vetmedica, St. 
Joseph, MO, USA) for 3 days post-surgery. Subcutaneous 0.9% sterile saline was 
administered as necessary to maintain hydration. Catheters were flushed Monday-Thursday 
with 0.2 ml of 0.9% sterile saline containing 30.0 IU/ml of the anticoagulant heparin and 67 
mg/ml of the antibiotic Timentin (SmithKline Beecham Pharmaceuticals, Philadelphia, PA). 
To preserve catheter patency on weekends and holidays, catheters were filled with 0.08 ml 
of a locking solution consisting of glycerol (Sigma-Aldrich, St. Louis, MO, USA) and 
heparin (1000 mg/ml) in a 3:1 ratio. This solution was removed and replaced with 0.2 ml of 
a 3.0 IU/ml heparinized 0.9% saline solution prior to resumption of the next behavioral 
session. Catheter patency was assessed weekly by withdrawing blood and/or infusion of 0.1 
ml (10 mg/ml) of methohexital sodium (JHP Pharmaceuticals, Rochester, MI, USA), and 
noting the rapid loss of muscle tone. In the event that patency was lost, catheters were 
repaired or replaced under surgical anesthesia and post-operative care, as above. Because a 
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small number of rats (9 total) used for the set shifting procedures died prior to completing all 
cocaine self-administration procedures, group sizes for the cocaine maintenance, extinction 
and reinstatement tests (described below) were n=8 for vehicle- and d-amphetamine-treated 
WKY and WIS as well as for vehicle-treated SHR; the group size for d-amphetamine-treated 
SHR was n=9.
2.5.2. Maintenance testing—On P77, rats began self-administration training for 0.3 
mg/kg cocaine under FR1 schedule contingencies. Self-administration sessions were 
initiated with illumination of the house light and onset of white noise (70 dB), which served 
as a background contextual cue. Cocaine infusions coincided with 20-sec presentation of the 
stimulus light, while the house light was extinguished. During this period, additional cocaine 
infusions could not be earned to reduce risk of accidental overdose. The house light was re-
illuminated and the stimulus light extinguished after the 20-sec timeout period. Rats were 
gradually trained to a terminal fixed-interval (FI) based second-order schedule, designated 
FI 5-min [FR5:S]. Under this schedule, every fifth lever press (FR5) produced a 2-sec cue 
light, and the first FR5 response unit completed after the 5-min FI elapsed resulted in a 
cocaine infusion coinciding with 20-sec presentation of the stimulus light, after which the FI 
5-min component was again in effect. Self-administration sessions were 2 hr in duration and 
conducted once daily, Monday–Friday, during the light phase at approximately the same 
time each day. Training under the second-order schedule continued until rats reached stable 
baseline levels of responding, defined as ≤ 15% variation in active lever responding and ≤ 
33% of total responding on the inactive lever, for a minimum of 5 consecutive sessions.
2.5.3. Extinction training—Following establishment of maintenance baselines, rats 
underwent response extinction training. During this phase, the house light was illuminated 
throughout the session, but the stimulus light and white noise were not presented, and 
cocaine infusions could not be earned. Lever responding therefore had no consequences. 
Extinction sessions were 2 hr in duration, and conducted once daily, Monday–Friday. 
Extinction training continued for a minimum of 10 sessions and until criterion was reached, 
defined as active lever responding that was ≤ 10% of the maintenance baseline for 3 
consecutive sessions. If rats did not reach criterion, a maximum of 21 extinction sessions 
was imposed.
2.5.4. Reinstatement testing—Following achievement of extinction criterion, rats 
underwent cue-induced reinstatement testing. During this phase, the discrete stimulus light 
and contextual white noise cues were presented under contingencies identical to self-
administration training under the second-order schedule, but cocaine infusions could not be 
earned. Reinstatement testing sessions were 1 hr in duration and conducted once daily, 
Monday-Friday. All rats underwent 7 reinstatement sessions.
2.6. Data analysis—Each measure in the set shifting and cocaine self-administration 
studies was analyzed using two-factor (strain x treatment, or treatment x day) or three-factor 
(strain x treatment x phase, or strain x treatment x day) repeated-measures ANOVA, 
followed by post-hoc Tukey tests. The Tukey is a conservative test that controls for type-1 
error when multiple comparisons are made [73]. In the strategy set shifting task, dependent 
Jordan et al. Page 7
Behav Brain Res. Author manuscript; available in PMC 2017 January 15.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
measures included number of trials completed to reach criterion, latency to reach criterion 
(included the time for omitted trials), ratio of correct to incorrect lever responses (choice 
accuracy), and error subtypes. These measures of performance reflect the primary outcome 
measure, flexible learning, during the set shift and reversal learning phases of the task [52]. 
In addition to measures of flexible learning, the average lever press reaction time, variability 
in lever press reaction time, and number of omitted trials were recorded. Higher values in 
these measures are thought to represent attentional lapses during testing in children and 
teens with ADHD [74,75]. Several set shifting task measures failed the Shapiro-Wilk 
normality test and data were subsequently square root transformed prior to analysis. Square 
root-transformed measures included omissions, reaction time, reaction time variability and 
choice accuracy in the initial set formation phase; trials to criterion, latency to criterion, 
omissions, reaction time variability, choice accuracy, regressive and never-reinforced errors 
for the set shift phase; and trials to criterion, latency to criterion, omissions, reaction time 
variability, choice accuracy, and perseverative and regressive errors in the reversal learning 
phase. Data were normally distributed following square root transformation. Dependent 
measures for cocaine self-administration included number of cocaine infusions earned, 
active and inactive lever responses, and number of sessions required to reach extinction 
criterion.
Errors in the set shifting task were coded by subtype for the set shift and reversal learning 
phases [22,52]. During the set shift phase, perseverative and regressive errors were recorded 
when rats pressed a lever with the stimulus light illuminated above it on trials that required 
pressing of the opposite lever. Errors were perseverative when rats pressed the incorrect 
lever on six or more trials per block of eight trials. Once rats made five or fewer incorrect 
choices in a block of eight trials for the first time, the incorrect lever choices in subsequent 
blocks were then scored as regressive errors. Never-reinforced errors were recorded when a 
rat pressed the incorrect lever on trials when the correct lever had the stimulus light 
illuminated above it (i.e., a choice that was not reinforced during either the initial set or set 
shift phase). During the reversal learning phase, errors were examined in blocks of 16 trials 
and consisted of perseverative and regressive errors [22,76]. Once rats made ten or fewer 
incorrect choices in a block of 16 trials for the first time, the incorrect lever choices in 
subsequent blocks were then scored as regressive errors. Never-reinforced errors are not 
possible during the reversal-learning phase. Perseverative errors are an index of how well 
the previously acquired strategy is suppressed, regressive errors are an index of how well the 
new strategy is maintained, and never-reinforced errors are an index of how well the new 
strategy is acquired [52].
3. Results
3.1. Experiment 1: Strategy set shifting in adolescence
3.1.1. Initial set formation—Figure 1 depicts data obtained during the initial set 
formation phase of the strategy set shifting task. Strains differed in trials to criterion (F(2, 
52) = 6, p ≤ 0.005), latency to criterion (F(2, 52) = 5.8, p ≤ 0.005), trial omissions (F(2, 52) 
= 4.5, p ≤ 0.01), average reaction time (F(2, 52) = 9.2, p ≤ 0.001), and reaction time 
variability (F(2, 52) = 9.3, p ≤ 0.001). No strain differences were observed for choice 
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accuracy. Adolescent SHR and the WIS control required fewer trials to reach criterion (p ≤ 
0.008 and 0.01, respectively) and had shorter latencies to reach criterion (p ≤ 0.01) than the 
WKY control. Both SHR and the WKY control exhibited slower reaction time and greater 
reaction time variability than the WIS control (p ≤ 0.01), and the WKY control also made 
more trial omissions than the WIS control (p ≤ 0.01). d-Amphetamine treatment did not alter 
performance on any measure across strains during initial set formation.
3.1.2. Set shift—Figure 2 illustrates data from the set shift phase of the strategy set 
shifting task. Strains differed in trials to criterion (F(2, 52) = 4.8, p ≤ 0.01), latency to 
criterion (F(2, 52) = 6.4, p ≤ 0.003), trial omissions (F(2, 52) = 3.7, p ≤ 0.03), average 
reaction time (F(2, 52) = 10, p ≤ 0.001), and reaction time variability (F(2, 52) = 8.7, p ≤ 
0.001). No strain differences were observed for choice accuracy. Adolescent SHR and the 
WIS control required more trials to reach criterion (ps ≤ 0.02) and had longer latencies to 
reach criterion (p ≤ 0.009 and 0.008, respectively) than the WKY control. Adolescent SHR 
also exhibited slower reaction time and greater reaction time variability compared to the 
WKY and WIS controls (p ≤ 0.05). Moreover, SHR made more omissions (p ≤ 0.03) than 
the WKY control.
For latency to criterion, there was a trend towards a strain X treatment interaction (F(2, 52) 
= 2.7, p ≤ 0.07) and further testing revealed that vehicle-treated WKY took less time to 
reach criterion than vehicle-treated WIS and SHR (p ≤ 0.01 and 0.001, respectively). d-
Amphetamine treatment reduced latency to criterion in adolescent SHR only (p ≤ 0.01). 
There also was a trend towards a strain X treatment interaction (F(2, 52) = 2.7, p ≤ 0.07) for 
choice accuracy, which for the adolescent SHR improved relative to vehicle following d-
amphetamine treatment (p ≤ 0.01).
With respect to regressive errors, there was a significant strain X treatment interaction (F(2, 
52) = 3.3, p ≤ 0.04). Vehicle-treated SHR made more regressive errors than vehicle-treated 
WKY (p ≤ 0.01). Compared to vehicle treatment, d-amphetamine reduced regressive errors 
in SHR only (p ≤ 0.006). For never-reinforced errors, both strain (F(2, 52) = 4.6, p ≤ 0.01) 
and treatment (F(1, 52) = 3.9, p ≤ 0.05) effects were observed. Overall, the WIS control 
made more never-reinforced errors than the WKY control (p ≤ 0.01). In addition, rats treated 
with d-amphetamine made fewer never-reinforced errors than vehicle-treated rats overall (p 
≤ 0.05). Although the strain X treatment interaction was not significant, further testing 
revealed that SHR treated with d-amphetamine made fewer never-reinforced errors than 
vehicle-treated SHR (p ≤ 0.04). No strain or treatment differences were observed for 
perseverative errors during the set shift phase.
3.1.3. Reversal Learning—Figure 3 shows data obtained during the reversal learning 
phase of the strategy set shifting task. Strain differences were observed in trials to criterion 
(F(2, 52) = 3.8, p ≤ 0.03), latency to criterion (F(2, 52) = 5.1, p ≤ 0.01), trial omissions (F(2, 
52) = 4.7, p ≤ 0.01), average reaction time (F(2, 52) = 6.7, p ≤ 0.003), and reaction time 
variability (F(2, 52) = 6.4, p ≤ 0.003). No strain differences were observed for choice 
accuracy. Overall, adolescent SHR required fewer trials to reach criterion than the WIS 
control (p ≤ 0.02), and both the WKY control and SHR had shorter latencies to reach 
criterion than the WIS control (p ≤ 0.01 and 0.03, respectively). Adolescent WKY also made 
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fewer trial omissions than the WIS control (p ≤ 0.01), and SHR exhibited slower and more 
variable reaction times than the WKY control (p ≤ 0.002 and 0.003, respectively). For 
perseverative errors, there was a trend towards a main effect of strain (F(2, 52) = 2.9, p ≤ 
0.06) and further testing revealed that SHR made fewer perseverative errors than the WIS 
control (p ≤ 0.05). No strain differences were observed for regressive errors. d-
Amphetamine treatment did not alter performance on any measure across strains during the 
reversal learning phase.
3.2. Experiment 2: Cocaine self-administration in adulthood
3.2.1. Maintenance testing—Figure 4 illustrates number of active lever responses and 
cocaine infusions during the maintenance-testing phase (last 5 sessions) of cocaine self-
administration in adulthood. At baseline, strains differed in active lever responding (F(2, 43) 
= 13.6, p ≤ 0.001), with adult SHR making more active lever responses than the WKY and 
WIS control strains (p ≤ 0.001 and 0.005, respectively). Analysis of cocaine intake also 
revealed strain differences (F(2, 43) = 12.3, p ≤ 0.001), with adult SHR earning more 
cocaine infusions than the WKY and WIS control strains (p ≤ 0.001 and 0.03, respectively). 
Inactive lever responses did not differ by strain (average = 45 ± 11; ≤ 14% of active lever 
responses). Adolescent d-amphetamine treatment did not affect any measure across strains 
during maintenance testing in adult rats.
3.2.2. Extinction training—Figure 5 depicts data obtained during response extinction 
training following the cocaine self-administration maintenance phase in adulthood. Strains 
differed in the number of sessions to reach the extinction criterion (F(2, 43) = 8.1, p ≤ 
0.001), with SHR requiring more sessions than the WKY or WIS controls (p ≤ 0.01 and 
0.001, respectively). Strain differences also were observed for active lever responses made 
during the extinction baseline (F(2, 43) = 4, p ≤ 0.02), which was the average of the last 
three extinction sessions and expressed as a percentage of the maintenance testing baseline. 
SHR and the WKY control made relatively more active lever responses than the WIS 
control during the extinction baseline (p ≤ 0.05 and 0.04, respectively), though all strains 
extinguished to less than 10% of the maintenance baseline level of responding. Inactive 
lever responses during the extinction baseline also differed by strain (F(2, 43) = 3.7, p ≤ 
0.03), with SHR making more inactive lever responses (31 ± 12) than the WIS control (6 ± 
1; p ≤ 0.03), but not the WKY control (9 ± 2). Adolescent d-amphetamine treatment did not 
alter any measure across strains during extinction training in adult rats.
3.2.3. Reinstatement testing—Figure 6 illustrates active lever responses during cue-
induced reinstatement testing following response extinction training in adulthood. Three-
way ANOVAs of active lever responding revealed a main effect of phase (F(1, 43) = 116, p 
≤ 0.001) and further testing indicated that in all strains, active lever responses were greater 
during the reinstatement phase than during the extinction phase (p ≤ 0.001). There was also 
a main effect of strain (F(2, 43) = 32.8, p ≤ 0.001) and reinstatement day (F(6, 252) = 2.5, p 
≤ 0.02). Subsequently, two-way ANOVAs (strain X treatment) were conducted for each day 
of reinstatement. On day 1 of reinstatement testing, a strain X treatment interaction was 
observed (F(2, 43) = 5, p ≤ 0.01). Further testing revealed that SHR reinstated more active 
lever responses than the WKY and WIS controls overall (p ≤ 0.001), and that adult SHR 
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treated with adolescent d-amphetamine reinstated fewer active lever responses than SHR 
treated with vehicle (p ≤ 0.003). However, this reduction in responding was not maintained 
across reinstatement sessions in amphetamine-treated SHR. For each subsequent day of 
reinstatement testing, strain differences were sustained (SHR > WKY = WIS; p ≤ 0.008). In 
WKY or WIS, adolescent d-amphetamine treatment did not alter active lever responses on 
day 1 or on any other reinstatement test day.
For inactive lever responses, a three-way ANOVA revealed a day X strain X treatment 
interaction (F(12, 252) = 2.2, p ≤ 0.01). Further testing indicated that, overall, SHR made 
more inactive lever responses than the WKY and WIS controls (p ≤ 0.03). Moreover, on day 
1 of reinstatement, adult SHR treated with adolescent d-amphetamine made fewer inactive 
lever responses than SHR treated with vehicle (p ≤ 0.006). In WKY and WIS, adolescent d-
amphetamine treatment did not alter inactive lever responses on day 1 or on any other 
reinstatement test day.
4. Discussion
The performance of SHR, WKY and WIS strain rats were compared on a strategy set 
shifting task during adolescence and for cocaine self-administration and cue reinstatement 
during adulthood. Treatment with d-amphetamine or vehicle was provided during 
adolescence, from P28 through P55, with rats arriving on P25 and housed individually. 
Upon arrival on P25, animals were allowed three days to acclimate to the new housing 
conditions. A three-day acclimation period is standard protocol in animal studies assessing 
cocaine self-administration [77], neurochemistry [78], as well as in studies using adolescent 
rats [79]. One potential issue this design raises is the role of early life stress (recent shipping, 
individual housing, food restriction during adolescence) on the outcome measures. Previous 
studies have shown that rats housed individually in caging with wire mesh flooring and with 
no daily handing were more impulsive than group-housed rats living in an enriched 
environment with pulp bedding and novel objects for play [80]. Although rats in the current 
study were housed individually and food-restricted during adolescence, they were handled 
daily and were provided some enrichment in the form of Aspen bedding in the home cage 
and exposure to food reinforcement in operant chambers. With respect to cocaine self-
administration, studies in outbred male rats have shown no reliable differences in individual- 
compared to pair- or group-housed peers [81,82]. In addition, although caloric restriction to 
90% body weight can enhance initial locomotor responses to cocaine injections in adult 
outbred rats, this effect is not sustained after repeated exposure to cocaine [83]. Food 
restriction during adolescence in the current study likely did not impact cocaine responses 
during adulthood, as the cocaine self-administration training sessions began 22 days after a 
return to ad libitum feeding and lasted for several weeks before testing began. Thus, even if 
potential early life stress were not fully mitigated by our procedures and study design, all 
three strains were handled equivalently, yet strain and treatment differences were found in 
the set shifting and cocaine self-administration tasks. It remains possible that strain 
differences in stress vulnerability (SHR > WKY > WIS) [84,85] contributed to strain 
differences in set shifting and cocaine self-administration behavior. However, in most cases, 
WKY had the best performance during the latter phases of the set shifting task and had 
similar performance to WIS during cocaine self-administration testing, which is inconsistent 
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with the rank order for stress vulnerability. Furthermore, early life stress has been shown to 
impact adolescent WKY and SHR differently, with WKY showing increased anxiogenic 
effects and SHR showing resilience to the anxiogenic effects of early life stress [86]. Thus, 
exposure to early life stress in the current study does not appear to systematically account 
for the strain and treatment differences in performance on the strategy set shifting task 
during adolescence and in cocaine self-administration and cue reinstatement tests during 
adulthood.
4.1. Strain differences in strategy set shifting in adolescence
During initial set formation, adolescent SHR needed fewer trials and shorter latencies to 
reach criterion relative to the WKY control, consistent with prior work in our laboratory 
[22]. Trial omissions also were fewer in SHR relative to the WKY control. However, SHR 
exhibited slower and more variable reaction times than the WIS control, suggesting that at 
this initial stage of learning the SHR display attentional lapses. These results are consistent 
with observations in individuals with ADHD who demonstrate high inter-individual reaction 
time variability, and in some studies, slower reaction time compared to controls without 
ADHD [87]. High reaction time variability is, moreover, a robust and highly consistent 
feature of ADHD, and may contribute to other symptoms such as poor sustained attention, 
behavioral inhibition, and working memory deficits [87]. Interestingly, these symptoms have 
been attributed to altered frontal cortex and DAT functioning [87,88], which also are 
observed in SHR [27,89–92].
The SHR may more readily respond than WKY for reinforcement under task conditions that 
do not require complex flexible learning, such as during acquisition of the initial attentional 
set [22,93]. However, performance in WKY also was consistently worse than performance 
in the WIS control during this initial stage of learning. Although WKY is frequently used as 
an inbred control strain for SHR [26], the WKY, particularly from Charles River 
Laboratories USA, has been used also as a model of anxiety, depression, and more recently, 
autism spectrum disorder [94,95]. Compared to outbred rat strains, WKY show reduced 
locomotor activity and social exploratory behavior in the open field test, elevated plus maze, 
and three-chamber social interaction test, as well as increased learned helplessness and 
immobility in forced swim and defensive burying paradigms [95–97]. Furthermore, in 
reinforcement-based tasks, WKY earn fewer sucrose pellets than WIS under FR 1 and 
progressive ratio schedules [98]. Behavioral abnormalities exhibited by WKY have been 
attributed to reduced cortical and hippocampal volume and plasticity, decreased D1 receptor 
and DAT binding in striatum, and decreased dopamine and dopamine metabolite levels in 
PFC, relative to outbred rat strains [99–102]. Importantly, the initial set formation of the 
strategy set shift task requires dopaminergic projections to frontal cortex, as 6-OHDA 
lesions in frontal cortex, but not caudate nucleus, impaired acquisition of an initial set [103]. 
Decreased dopamine levels in frontal cortex of WKY [100] may contribute, therefore, to 
slower learning of the initial strategy set in this strain. Although the WKY has been 
suggested to be the most appropriate comparator strain for SHR [22,26], current findings 
emphasize the importance of concurrent evaluation of WKY and an outbred control when 
examining set shifting performance in SHR.
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In contrast to the initial set formation, the set shift phase of the task necessitates greater 
flexible learning, requiring rats to switch responding from a previously learned visual 
strategy to a spatial strategy. Consistent with previous studies [22], adolescent SHR showed 
the greatest deficits during the set shift phase, displaying poorer flexible learning and more 
attentional lapses than both control strains. On the Wisconsin Card Sorting Task, individuals 
with ADHD similarly exhibit poor flexible learning, making more perseverative responses 
and completing fewer categories than typically developing controls [75,104,105]. Poor 
flexible learning and other ADHD-related symptoms, such as hyperactivity, inattention, low 
motivation, and poor motor timing and response inhibition, may arise from abnormal neural 
activation and connectivity in frontostriatal circuitry both in humans and SHR [38,106,107].
During the set shift phase, WKY reached learning criterion faster than both WIS and SHR, 
and made fewer errors than WIS. It is possible that WKY exhibit superior flexible learning 
in strategy shifting compared to WIS or SHR. However, given that WKY were slower in 
acquiring the initial set, it is also possible that WKY experienced less proactive interference 
during the set shift than WIS or SHR. Proactive interference from a previously relevant 
stimulus dimension exacerbates cognitive inflexibility when individuals are required to 
attend to a new stimulus feature [108]. Previous work identified reduced proactive 
interference in WKY in an eyeblink conditioning paradigm, whereby pre-exposure to 
unconditioned or conditioned stimuli did not alter acquisition rate of the eyeblink response 
in WKY, but slowed acquisition in outbred Sprague-Dawley rats [109]. Though it is unclear 
to what degree proactive interference in classical conditioning generalizes to operant 
conditioning, weakened acquisition, memory storage, or retrieval of the initially reinforced 
visual strategy by WKY in the current study could plausibly lead to reduced proactive 
interference during subsequent testing phases, manifesting as fewer errors and an apparently 
faster ability to acquire new response strategies [110].
Reduced proactive interference may also help to explain some of the current observations 
during the reversal learning phase of the set shift task. During reversal learning, SHR 
continued to show slower and more variable reaction times, consistent with the ADHD 
phenotype. However, WKY and SHR reached the reversal learning criterion faster than 
WIS. Moreover, during this phase WKY made fewer trial omissions, and SHR fewer 
perseverative errors, than WIS rats. It is possible that, relative to SHR and WKY, WIS 
exhibit deficits in reversal learning, which is dependent on OFC functioning [76]. However, 
an alternative explanation is that WKY and SHR experienced less proactive interference 
than WIS during reversal learning. Deficient learning or memory of the previously acquired 
behavioral strategies by WKY and SHR would lead to the appearance of superior 
performance relative to WIS during the reversal learning phase. Conversely, normative 
learning and retrieval of the previously acquired behavioral strategy by WIS would lead to 
increased proactive interference, resulting in slower speed of reversal learning and a greater 
number of perseverative errors as observed in the current study.
4.2. Effects of d-amphetamine treatment on strategy set shifting in adolescence
d-Amphetamine improved several measures of flexible learning in adolescent SHR during 
the set shift phase. Specifically, SHR treated with d-amphetamine reached the set shift 
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learning criterion faster, were more accurate in response choices, and made fewer regressive 
and never-reinforced errors than vehicle-treated SHR. In children with ADHD, treatment 
with d-amphetamine, as well as other ADHD medications, was found to normalize abnormal 
striatal glutamate levels that may contribute to ADHD-related symptoms in both humans 
and SHR [56,91,107,111–113]. However, future work is needed in the SHR model to 
determine whether d-amphetamine alters glutamate signaling in striatum or substantia nigra. 
Although d-amphetamine did not improve reaction time measures or reduce the number of 
omitted trials in SHR during any phase of the set shift task, rarely are all ADHD symptoms 
alleviated by drug therapy [114]. It is possible that a higher d-amphetamine dose would 
improve these additional ADHD-related deficits in SHR [49], but higher doses may also 
produce plasma levels, monoamine responses, and behavioral consequences that are not 
clinically relevant [68]. In adult outbred rats, prior adolescent (P27-P45) or adult (P95-P103) 
treatment with 3 mg/kg d-amphetamine (i.p.) every other day produced sensitization to a d-
amphetamine challenge, and increased errors during reversal learning of a compound 
stimulus discrimination [115]. Because reversal learning is dependent on OFC [76], these 
findings suggest that higher doses of d-amphetamine may impair OFC functioning long-term 
[115]. Moreover, the same 3 mg/kg adolescent d-amphetamine treatment regimen reduced 
choice latency during attentional set shifting, and increased perseverative responding during 
strategy set shifting and differential reinforcement of low rates of responding (DRL) tasks, 
suggesting that higher doses of d-amphetamine heighten the saliency of reward-related cues 
[115,116]. Interestingly, adolescent exposure to 3 mg/kg d-amphetamine also reduced trials 
to criterion during set shifting and reversal learning in adulthood, compared to vehicle-
treated rats as well as rats receiving d-amphetamine in adulthood [115]. These findings 
further confirm that psychostimulants differentially affect adolescents relative to adults [51], 
and also emphasize the importance of task selection when considering the long-term effects 
of d-amphetamine and its potential therapeutic use relative to other ADHD medications.
In contrast to d-amphetamine, a past study shows that adolescent treatment with the 
stimulant methylphenidate improved flexible learning in adolescent SHR only during the 
initial set formation phase [22]. Conversely, the non-stimulant atomoxetine improved 
flexible learning and reduced the number of omitted trials in the SHR during the set shift 
phase [22], more similar to the current observations with d-amphetamine. The ability of d-
amphetamine and atomoxetine to improve flexible learning in adolescent SHR may relate in 
part to direct effects not only on glutamatergic signaling, but also on DAT function in PFC. 
Chronic treatment with atomoxetine during adolescence decreased DAT function in OFC 
and striatum of SHR [35]. In contrast, chronic treatment with methylphenidate during 
adolescence increased DAT function in mPFC of SHR [62], potentially exacerbating pre-
existing elevations of DAT [27,92]. We hypothesize that chronic treatment with d-
amphetamine during adolescence produces long-term decreases in DAT function and 
expression, similar to that observed after atomoxetine treatment. Although the effect of d-
amphetamine on PFC DAT function in SHR is unknown, recently, acute amphetamine 
infusions were found to reduce DAT function and expression in nucleus accumbens of adult 
outbred rats [117]. Importantly, activation of post-synaptic D1 and D2 receptors in mPFC 
facilitates flexible learning [118], as infusion of D1 and D2 antagonists in mPFC impairs set 
shifting performance in outbred rats [119,120]. Therefore, by decreasing DAT function and 
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elevating dopaminergic tone, adolescent d-amphetamine may produce optimal activation at 
D1 and D2 receptors in mPFC of SHR, thereby improving flexible learning during the set 
shift. However, additional studies are needed to test our hypothesis in mPFC of the SHR 
model, using a chronic dosing regimen of d-amphetamine during adolescence that is 
clinically relevant to ADHD.
4.3. Strain differences in cocaine cue reactivity in adulthood
The current study replicated previous findings suggesting that SHR are a viable model for 
comorbid ADHD and cocaine abuse risk. During maintenance testing under a second-order 
schedule, SHR earned more cocaine infusions and made more cocaine-seeking responses 
than WKY and WIS control, consistent with our prior work [34]. SHR also required more 
sessions than WKY or WIS to reduce lever responding during extinction training. This is 
consistent with prior findings that SHR, like individuals with ADHD, exhibit slower 
extinction rates than controls, possibly as a result of low sensitivity to changes in 
reinforcement contingencies and abnormal nigrostriatal dopamine functioning [121–123]. 
Lastly, SHR exhibited greater reinstatement of cocaine-seeking responses than WKY and 
WIS upon re-exposure to cocaine-paired cues, in the absence of cocaine reinforcement. 
These results suggest that SHR are more reactive to cocaine-paired cues than WKY or WIS. 
Although studies on cocaine cue reactivity in ADHD are lacking, cigarette smokers with 
ADHD report more frequent encounters with smoking-associated cues and perceive a 
stronger relationship between cues and smoking motivation [124], suggesting heightened 
drug cue reactivity relative to smokers without ADHD. However, further studies evaluating 
physiological measures such as skin conductance, heart rate, or hemodynamic neural 
responses to drug cues in individuals with ADHD are necessary to confirm this hypothesis.
4.4. Effects of adolescent d-amphetamine treatment on cocaine cue reactivity in adulthood
Adolescent d-amphetamine did not alter cocaine intake, cocaine seeking, or response 
extinction rates in adult rats of any strain, with the exception that adult SHR treated with d-
amphetamine during adolescence made fewer cocaine-seeking responses on the first day of 
reinstatement testing compared to vehicle-treated SHR. Together, these findings suggest that 
adolescent d-amphetamine treatment does not further increase cocaine abuse risk in adult 
SHR. The effects of adolescent atomoxetine treatment were similar to d-amphetamine; 
however, cocaine-seeking responses were reduced across the entire 7-day reinstatement test 
phase in adult SHR after adolescent atomoxetine [34]. In contrast, adolescent 
methylphenidate treatment speeded acquisition of cocaine self-administration, increased 
cocaine intake, and augmented the efficacy and motivating influence of cocaine 
reinforcement in adult SHR under FR and progressive-ratio schedules [30,33]. Under a 
second-order schedule, adolescent methylphenidate treatment also further increased cocaine 
intake during maintenance testing in adult SHR, but it did not further enhance cocaine-
seeking behavior during reinstatement testing [34]. The differential effects of adolescent d-
amphetamine, atomoxetine, and methylphenidate on cocaine-seeking behavior in adulthood 
might relate in part to differential long-term effects on DAT function within PFC, as 
reviewed above. It is probable that additional neurochemical adaptations contribute to the 
long-term effects of ADHD medications on cocaine abuse risk, such as changes at post-
synaptic receptors or norepinephrine and serotonin transporters, to which d-amphetamine 
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also potently binds and reverses transport [43,125]. However, future investigations are 
needed to investigate these changes in SHR.
5. Conclusions
Questions regarding long-term effects of adolescent ADHD medication on later substance 
use disorders, and particularly cocaine abuse risk, have been historically difficult to examine 
in a systematic manner in individuals with ADHD. The results of the current investigation, 
together with previous work, indicate that the SHR has important heuristic value in 
modeling aspects of cognitive dysfunction, cocaine abuse risk, and effects of d-amphetamine 
treatment for adolescents with ADHD. The failure of a clinically relevant dose of d-
amphetamine to alter set shifting behavior in adolescence or cocaine cue reactivity in 
adulthood of WKY and WIS control strains emphasizes the importance of employing an 
appropriate animal model wherever feasible when investigating the effects of ADHD 
medications.
Although cocaine cue reactivity, as examined in the current study, is an important aspect of 
cocaine abuse risk, the most robust effects of adolescent methylphenidate treatment were 
observed during the acquisition of cocaine self-administration and on the efficacy and 
motivating influence of cocaine reinforcement in adulthood [30,33]. Future studies are 
needed to assess whether adolescent d-amphetamine treatment alters other important aspects 
of cocaine abuse risk in adult SHR by examining full cocaine dose-response functions using 
fixed and progressive ratio schedules of reinforcement. Nonetheless, the current results 
suggest that d-amphetamine may be an alternative stimulant medication to methylphenidate 
for newly diagnosed teenagers with ADHD. While concern has been raised regarding the 
abuse liability of d-amphetamine as a prescription medication in itself, there is little actual 
abuse of d-amphetamine by ADHD patients [43]. The pharmacokinetics of orally 
administered d-amphetamine make the drug less reinforcing than other stimulants, such as 
cocaine or methamphetamine, and clinically relevant doses of d-amphetamine are unlikely 
to produce the euphoria associated with compulsive drug use [43]. Moreover, the pro-drug, 
lisdexamfetamine (Vyvanse®), has recently been developed to further deter abuse, by 
requiring enzymatic hydrolysis within red blood cells in order to be converted into 
psychoactive d-amphetamine [43,126].
Illicit drug use costs the United States over $193 billion each year [127]. Nearly two-thirds 
of treatment-seeking drug users report sampling drugs before age 20 [128,129]. Thus, with 
approximately 1,600 teens and adults initiating cocaine use each day [130], it is critically 
important to reduce the risk of cocaine abuse, particularly in vulnerable populations such as 
those with ADHD. Application of our preclinical findings to a clinical setting could help 
minimize the risk of SUD in ~700,000 individuals, which is the estimated number of first-
time ADHD diagnoses in adolescents aged 12–17 [131].
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Highlights
• Adolescent SHR exhibited set shift deficits compared to WKY and WIS 
controls
• Low dose d-amphetamine improved set shift performance only in adolescent 
SHR
• During adulthood, cocaine seeking and intake were greater in SHR than controls
• Adolescent d-amphetamine did not increase cocaine seeking or intake in adult 
SHR
• d-Amphetamine may be an alternate to methylphenidate for teens diagnosed 
with ADHD
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Fig. 1. 
Trials to criterion, latency to criterion, trial omissions, lever press reaction time, variability 
in reaction time, and choice accuracy during initial set formation in adolescent WKY, WIS, 
and SHR following vehicle or d-amphetamine treatment (Mean ± SEM). & p ≤ 0.05 
compared to WKY overall. # p ≤ 0.05 compared to WIS overall.
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Fig. 2. 
Trials to criterion, latency to criterion, trial omissions, lever press reaction time, variability 
in reaction time, choice accuracy, and error subtypes during the set shift phase in adolescent 
WKY, WIS, and SHR following vehicle or d-amphetamine treatment (Mean ± SEM). * p ≤ 
0.05 compared to both other strains. & p ≤ 0.05 compared to WKY overall. $ p ≤ 0.05 
compared to vehicle-treated WKY. ^ p ≤ 0.05 compared to vehicle-treated SHR.
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Fig. 3. 
Trials to criterion, latency to criterion, trial omissions, lever press reaction time, variability 
in reaction time, choice accuracy, and error subtypes during the reversal learning phase in 
adolescent WKY, WIS, and SHR following vehicle or d-amphetamine treatment (Mean ± 
SEM). & p ≤ compared to WKY overall. # p ≤ 0.05 compared to WIS overall.
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Fig. 4. 
Active lever responses and cocaine infusions during cocaine self-administration 
maintenance testing under a second-order schedule (Mean ± SEM). Experiments were 
conducted in adult WKY, WIS, and SHR following vehicle or d-amphetamine treatment 
during adolescence. * p ≤ 0.05 compared to both other strains.
Jordan et al. Page 28
Behav Brain Res. Author manuscript; available in PMC 2017 January 15.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Fig. 5. 
Number of sessions required to reach extinction criterion and active lever responses during 
the extinction baseline expressed as a percentage of the maintenance baseline (Mean ± 
SEM). Experiments were conducted in adult WKY, WIS, and SHR, following vehicle or d-
amphetamine treatment during adolescence. * p ≤ 0.05 compared to both other strains. # p ≤ 
0.05 compared to WIS overall.
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Fig. 6. 
Active lever responses during the extinction baseline (Ext) and each reinstatement test 
session (Mean ± SEM). Experiments were conducted in adult WKY, WIS, and SHR 
following vehicle or d-amphetamine treatment during adolescence. * p ≤ 0.05 compared to 
both other strains. ^ p ≤ 0.05 compared to vehicle-treated SHR.
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